Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study

Rossignol, Louise; Vaux, Sophie; Maugat, S.; Blake, Alexandre; Barlier, Roxane; Heym, Béate; Strat, Yann Le; Blanchon, Thierry; Hanslik, Thomas; Coignard, B.

doi:10.1007/s15010-016-0910-2

Cited by 55 publications

(42 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another author confirmed that only four pregnant patients with UTI were included in their study and none of them were diagnosed to have bacterial culture indicating ESBL infection . In one study from France, of nine pregnant patients, five had positive urine cultures and none of them were ESBL producers . The authors of eight studies did not reply …”

Section: Resultsmentioning

confidence: 97%

See 1 more Smart Citation

Extended‐spectrum beta‐lactamase (ESBL)‐producingEnterobacteriaceaeand urinary tract infections in pregnant/postpartum women: A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background Urinary tract infections (UTI) and asymptomatic bacteriuria (AB) during pregnancy can result in considerable maternal and foetal adverse outcomes. Production of extended‐spectrum beta‐lactamase (ESBL) is a major antibiotic resistance mechanism by Enterobacteriaceae. Objectives To determine the global prevalence of ESBL‐producing (ESBL‐P) Enterobacteriaceae in symptomatic UTI/AB among pregnant/postpartum females. Data sources A systematic review of the PubMed, Embase, Scopus, WOS (Web of Science), ProQuest and the grey literature was conducted. Study selection and data extraction Studies that reported the frequency of ESBL‐P Enterobacteriaceae in pregnant/postpartum women with UTI and/or AB were eligible. First, the titles and abstracts of the retrieved articles were reviewed. Then, the full texts of the remained articles were reviewed. Synthesis In order to estimate the pooled prevalence and the 95% confidence interval (95% CI), meta‐analysis was performed using the random‐effects model. Results Twenty‐three studies (six from Africa, two from North America, one from South America, 12 from Asia and two European studies) that reported data on 20 033 Enterobacteriaceae strains were included. The pooled prevalence of ESBL‐P Enterobacteriaceae was 25% (95% CI 18%, 32%); I2 = 98.8%. The estimated prevalence (95% CI) rates were 45% (22, 67%) in Africa, 33% (22, 44%) in India, 15% (6, 24%) in other Asian countries, 5% (2, 8%) in Europe, 4% (1, 11%) in South America and 3% (1, 5%) in North America (P < .001). This estimate was 21% (95% CI 11, 31%) in patients with symptomatic UTI and it was 28% (95% CI 15, 41%) in patients with AB (P = .40). Conclusions The prevalence of ESBL‐P Enterobacteriaceae among pregnant women with UTI/AB was significant and geographic region was a major source for heterogeneity. The findings could be taken into account by healthcare providers and programmers in the management and antibiotic selection of UTI/AB during pregnancy, especially in high prevalence areas.

show abstract

Section: Resultsmentioning

confidence: 97%

“…50 In one study from France, of nine pregnant patients, five had positive urine cultures and none of them were ESBL producers. 51 The authors of eight studies did not reply. 52-59 Figure 1 shows the flowchart that describes the process of inclusion of the studies.…”

Section: Esbl-producing Enterobacteriaceaementioning

confidence: 99%

Extended‐spectrum beta‐lactamase (ESBL)‐producingEnterobacteriaceaeand urinary tract infections in pregnant/postpartum women: A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Still, current trends show increasing rates of resistance to various antimicrobial agents independently of pathogen all over the world. The effective initial treatment of UTI might prevent the rapidly increasing bacterial resistance to antimicrobial drugs [8, 10]. Hooton et al [11] postulated in 2004 that increased use of fluoroquinolones would lead to decrease of efficacy to this class of antimicrobial drugs.…”

Section: Resultsmentioning

confidence: 99%

“…Disk-diffusion tests were used for resistance and susceptibility testing with application of appropriate disks, including ampicillin (10 μ g), trimethoprim/sulfamethoxazole (11.25 μ g/23.75 μ g), ciprofloxacin (5 μ g), amoxicillin/clavulanic acid (20 μ g/10 μ g), nitrofurantoin (100 μ g), cephalexin (30 μ g), and cefuroxime (30 μ g). Extended-spectrum β -lactamase (ESBL) isolates were identified by specific polymerase chain reaction (PCR) and sequencing as described in the literature [8]. The obtained isolates were identified using standard methods, via a commercial bacterial identification system (Vitek 2 Compact, BioMérieux, France).…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial Resistance Patterns in Women with Positive Urine Culture: Does Menopausal Status Make a Significant Difference?

Miotła

Romanek-Piva

Bogusiewicz

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Aim. Urinary tract infection (UTI) is considered one of the most common bacterial infections in women. The aim of this study was to investigate the types of uropathogens present, as well as the degree of antimicrobial drug resistance seen among premenopausal (n = 2748) and postmenopausal (n = 1705) women with uncomplicated UTI. Methods. Urinary samples (n = 4453) collected from women with UTI were analyzed in terms of uropathogens present. These were considered as positive if bacterial growth was ≥105 colony forming units (CFUs)/mL. Susceptibility and resistance testing for commonly used antibiotics was subsequently assessed. Results. The most common uropathogens cultured from urine samples were Escherichia coli (65.5%), followed by Enterococcus faecalis (12.2%), Klebsiella pneumoniae (4.7%), and Proteus mirabilis (4.2%). The resistance to ampicillin exceeded 40%, independently of menopausal status. Of note, resistance to ciprofloxacin exceeded 25% among postmenopausal patients. Moreover, resistance of all uropathogens to commonly used antimicrobials was significantly higher in postmenopausal women. Conclusion. Due to the high resistance rate, ampicillin, ciprofloxacin, and the trimethoprim/sulfamethoxazole combination should be avoided in treating postmenopausal women affected by UTI without being indicated by initial urine culture report. Finally, cephalexin and cefuroxime are promising alternatives as initial treatment in postmenopausal women.

show abstract

“…Among the etiological factors inflammatory processes of reproductive system are multi-resistant factors or L-forms (protozoare, bacteria, fungi, viruses) with modified biological properties in the numerous microbe association are found more frequently, partially due to the non-systemic and unjustified administration of antibiotics, hormonal preparations, cytokines etc. [6,27].…”

Section: Etiological Factors Of Inflammatory Process Of Reproductive mentioning

confidence: 99%

Problem of urogenital mixed infections in reproductive aged women in current gynecology

Bysaha¹,

Korchynska²

2019

Reproductive Endocrinology

View full text Add to dashboard Cite

Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study

Abstract: ESBL had been found in a community population, and even though the rate was low, it represents a warning and confirms that surveillance should continue.

Cited by 55 publications

References 27 publications

Extended‐spectrum beta‐lactamase (ESBL)‐producingEnterobacteriaceaeand urinary tract infections in pregnant/postpartum women: A systematic review and meta‐analysis

Extended‐spectrum beta‐lactamase (ESBL)‐producingEnterobacteriaceaeand urinary tract infections in pregnant/postpartum women: A systematic review and meta‐analysis

Antimicrobial Resistance Patterns in Women with Positive Urine Culture: Does Menopausal Status Make a Significant Difference?

Problem of urogenital mixed infections in reproductive aged women in current gynecology

Contact Info

Product

Resources

About